Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion
Transplant Infectious Disease · 2026-03 · 28 (2)
DOI: 10.1111/tid.70169 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, online erschienen am 30.01.2026. Verfasst von Jacques Simkins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine/Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Latent Tuberculosis, Isoniazid, Rifampin, Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
A 4‐month course of rifampin is one of the recommended first‐line regimens for latent tuberculosis infection (LTBI). However, data on its use among kidney transplant candidates (KTC) remain limited.
Methods
We conducted a retrospective study of all KTC treated with either 4‐month rifampin or 9‐month isoniazid (INH) for LTBI at a transplant infectious disease clinic in Miami from January 1, 2021 to December 31, 2024. We assessed rates of treatment completion, adverse reactions leading to discontinuation of therapy, and transaminase elevation (> 2 times the upper limit of normal). The potential impact of rifampin on blood pressure (BP) in patients on antihypertensive drugs (AHD) known to interact with rifampin was also evaluated.
Results
A total of 66 patients were analyzed (49 [74%] in the INH group and 17 [26%] in the rifampin group). There was a trend towards higher treatment completion in the rifampin group compared to the INH group (16 [94%] vs. 34 [69%], p = 0.05). There was no difference in adverse reactions leading to treatment discontinuation. Transaminase elevations were not observed in the rifampin group, whereas they occurred in 3 (6%) of the INH group. Three patients experienced an increase in BP while receiving rifampin, leading to treatment discontinuation in one case.
Conclusion
A 4‐month rifampin course is an excellent option for LTBI among KTC due to its high completion rate and favorable liver safety profile; however, close monitoring for AHD interactions is essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine/Division of Infectious Diseases, University of Miami School of Medicine, Miami, Florida, USA.
- Department of Medicine/Katz Family Division of Nephrology and Hypertension, University of Miami School of Medicine, Miami, Florida, USA.
- Department of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
ORCID-Profile: Jacques Simkins, Julia Bini Viotti, Gaetano Ciancio, Mahmoud Morsi
Zitieren
APA
Simkins, J., Viotti, J. B., Natori, Y., Anjan, S., Mattiazzi, A., Ortigosa-Goggins, M., Guerra, G., Roth, D., Kupin, W., Pagan, J. A., Cabeza, F., Ciancio, G., Morsi, M., & Morris, M. I. (2026). Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion. Transplant Infectious Disease, 28(2). https://doi.org/10.1111/tid.70169
Vancouver
Simkins J, Viotti JB, Natori Y, Anjan S, Mattiazzi A, Ortigosa-Goggins M, et al. Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion. Transplant Infectious Disease. 2026;28(2). doi:10.1111/tid.70169
BibTeX
@article{Simkins2026,
author = {Simkins, Jacques and Viotti, Julia Bini and Natori, Yoichiro and Anjan, Shweta and Mattiazzi, Adela and Ortigosa-Goggins, Mariella and Guerra, Giselle and Roth, David and Kupin, Warren and Pagan, Javier A and Cabeza, Franco and Ciancio, Gaetano and Morsi, Mahmoud and Morris, Michele I},
title = {Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {2},
doi = {10.1111/tid.70169}
}
EUVIMED